Swaminathan, Shreya
Kisielewski, Amber M.
Nowroozzadeh, M. Hossein
Hallaj, Shahin
Lee, Daniel
Kolomeyer, Natasha N.
Myers, Jonathan S.
Razeghinejad, Reza
Article History
Received: 2 May 2023
Accepted: 16 June 2024
First Online: 23 June 2024
Declarations
:
: SS (Swaminathan), AK (Kisielewski), and MHN (Nowroozzadeh) have no disclosures; SH (Hallaj) is supported by the National Institute of Health, Bridge to AI common fund (grant number: OT2OD032644); DL (Lee): Consultant: Allergan, Inc. Research: Allergan, Inc. Speaker: Glaukos Corp; NK (Kolomeyer): Research: Guardion Health Sciences Inc, Consultant/Research: Allergan/AbbVie, Consultant: Alimera, Consultant: Regeneron, Consultant/Speaker: Bioge, Consultant/Speaker: Genentech, Consultant/Speaker: Iveric, Consultant: Vial; JSM (Myers): Consultant: Avisi, Olleyes; Research: AbbVie, Elios, Equinox, Glaukos, Guardian, Laboratories Thea, Nicox, Olleyes, Santen; RR (Razeghinejad): Equinox, Olleyes.
: Wills Eye Hospital; IRB #2021-110.
: N/A.